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risks from nanomedicines and adequacy of the
current guideline on environmental risk
assessment†
Indrani Mahapatra, *a Julian R. A. Clark,a Peter J. Dobson,bc Richard Owen,d
Iseult Lynch a and Jamie R. Leade
In the next couple of decades, nanotechnology-enabled healthcare applications will significantly influence
the diagnosis, prevention and treatment of human diseases. Since pharmaceutical products (PPs) have
been detected in various environmental compartments, and low-level chronic exposure to PPs has in-
duced adverse and sometimes unexpected effects on non-target organisms, the question of potential envi-
ronmental risks from increased usage of nanomedical products arises. The risks and benefits to patients
from nanomedicines are the focus of exhaustive evaluation by regulatory agencies; by contrast, risks to the
environment from nanomedicines are only briefly considered by regulators and are rarely discussed by
nanoscientists. To start to fill this gap, 66 experts from nanomedicine R&D, representatives of research
funding agencies and of institutions involved in safeguarding public health and the environment were inter-
viewed using a semi-structured questionnaire regarding possible hazards and risks from nanomedicine and
on the adequacy of current the environmental risk assessment (ERA) framework for medicines. The inter-
view recordings were transcribed verbatim and analysed via qualitative content analysis. Experts interviewed
commented that hazards were possible but risks were unlikely from nanomedicines due to expected mini-
mal exposure. They qualified their statements by comparing risks from nanomedicine with risks from nano-
materials in other industries, conventional pollutants and larger global issues like climate change. Regarding
adequacy of the current risk framework for assessment of environmental risks from nanomedicines, per-
ceptions of experts were more varied; some argued that complete overhaul of the ERA framework was re-
quired including changes in toxicity endpoints, whereas others suggested that the framework was ade-
quate, though some adjustments were needed.
Introduction
Nanomedicines are designed with new properties to enhance
their bio-availability and are enabled to be activated by exter-
nal stimuli.1,2 They have the potential to be of immense ben-
efit for improving human health, despite their current high
cost and the technical challenges in mass manufacture. It is
believed that in the next couple of decades, nanotechnology-
enabled health care applications will have a significant influ-
ence on diagnosis, prevention, and treatment of diseases.3,4
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Environmental significance
The possible environmental concentrations of nanomedicines containing gold nanoparticles for high-use and worst-case scenario was modelled to be in
the range 4–468 pg L−1 in surface waters, and 130–150 μg kg−1 in sewage sludge. Low level chronic exposure to pharmaceuticals can induce adverse and
sometimes unexpected effects on non-target organisms in the environment, raising concerns regarding the potential environmental risks from nano-
medicines. In this article, the opinions of 66 experts regarding possible risks arising from nanomedicines and the suitability of current environment risk
assessment (ERA) procedures for nanomedicines is presented. Experts noted that hazards were possible but that risks were unlikely from nanomedicines.
Recommendations regarding ERA for nanomedicines ranged from customisation of existing frameworks to complete overhaul.
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Due to their unique chemical and physical properties, such
as superparamagnetism and increased luminescence and op-
tical scattering because of plasmonic effects, metal nano-
particles can be used for in vitro and in vivo diagnostics5,6
and for cancer treatment.7 Carbon-based nanoparticle types –
micellar, liposomal, polymeric – can be used as drug delivery
vehicles for poorly soluble pharmaceuticals (e.g. albumin
nanoparticles for delivery of paclitaxel for treatment of meta-
static breast cancer),8 peptides, nucleotides and genes,9,10
and can be used in implants,11 vaccines,12 and in regenera-
tive medicine.13 Reformulation of approved drugs with nano-
particles can limit systemic toxicities by improved targeting
and cellular uptake.14 The many potential applications of
nanomedicine (including medical devices) have recently been
reviewed by Pelaz et al.15 Scientists at the Center of Drug
Evaluation Research (CDER) of the United States Food and
Drug Administration (USFDA) found an increase in drug ap-
plications of medicines containing nanomaterials over 45
years (1970 to 2015) and reported 359 nanomedicine applica-
tions submitted for approval. Their study showed that 40% of
the drug applications containing nanomaterials submitted
between 2010 and 2015 were for cancer treatment, followed
by treatments for immune, pain and inflammation indica-
tions (18%) and for infectious diseases (14%).16 However, in
addition to these positive uses, there is the possibility that
nanomedicine use could result in toxicities via different
modes of action – for example, different toxicodynamics or
pharmacodynamics, different organ and cellular distribu-
tions, or altered clearance rates (toxicokinetics or pharmaco-
kinetics). Additionally, the diversity of nanomaterial composi-
tions, sizes, surface coatings, and functionalities, can result
in varied toxic potentials (e.g. across different cell types and
organisms).
Patient safety, efficacy and quality resulting from use of
nanomaterials in drug products are addressed by the respon-
sible agencies, such as the USFDA,17 the European Medicines
Agency (EMA),18 and national medicinal agencies‡ in Europe.
However, the risks to the environment from such medicines
after use are seldom discussed (possibly due to the high per-
ceived benefits from nanomedicines outweighing potential
risks) despite the fact that pharmaceuticals products (PPs)
have been detected in various environmental compartments
– soil, biosolids, surface water and ground water.19,20 PPs
have been detected in surface waters of 41 countries,21 and it
has been found that low-level chronic exposure to PPs can
have adverse and sometimes unexpected effects on non-
target organisms.22,23 Surface water concentrations of iron ox-
ide nanoparticle (IONP) based MRI contrast agents, modelled
using 25% and 50% market penetration (i.e., replacement of
gadolinium-based MRI contrast agents), were estimated to be
3.1 ng L−1 and 8.4 ng L−1 for the years 2015 and 2020 respec-
tively in Germany.24 Annual surface water concentrations for
select gold nanoparticle-based medical applications were
modelled to be 5 and 470 pg L−1 for the US and UK respec-
tively.25 Many drug delivery and targeting applications in the
nanomedicine field have polymeric coatings, such as polyeth-
ylene glycol (PEG) which is used for its stealth properties and
stability in biological fluids,26 however, their very stability
and ability to escape an organism's biological barriers and
immune system raises the question as to whether nano-
medicines could pose risks to organisms in the environment
when they get released without any transformation, metabo-
lism or degradation. Very few studies have reported on the
interaction of nanomedicines with non-biotic components of
the environment and some (limited) ecotoxicology studies
have been done with nanomaterials representative of nano-
medicines25,27 although it is important to note that these
studies have not utilised the actual nanomedicine formula-
tions approved or in clinical trials.
Expert judgement is the preferred method to evaluate and
characterise risks in cases where uncertainties and data gaps
exist,28,29 which is largely the case with nanomaterials. In-
deed, many government agencies and national committees
with statutory or advisory responsibility for protecting human
health and the environment seek views from established sci-
entists or are composed from them; therefore, it was decided
to gather the perspectives of applied scientists, social scien-
tists, regulators, policymakers, and representatives of indus-
tries along the nanomedicine R&D spectrum on the potential
environmental impacts from nanomedicine. Also, for this
study, perceptions on the suitability of the current environ-
ment risk assessment framework was explored by conducting
semi structured interviews with sixty-six respondents (see
Methodology below).
There are varied views on the risks posed by nano-
medicine. In a study by Petersen and Anderson,30 experts
considered human health risks from medical applications to
be high by reasoning that injecting nanoparticles into human
bodies can cause unknown effects due to increased bio-
accumulation of active ingredients when compared to con-
ventional medicines, whereas in a survey-based study by
Siegrist et al.,31 it was found that experts rated risks from use
of nanomaterials in medicines to be low compared to risks
associated with nanomaterials in other areas such as food
packaging and sunscreens. This could perhaps be due to the
perceived beneficial effects of medicines, as noted above.
Similarly, Capon et al.32 showed that use of nanomaterials in
medicines was considered less risky by academics and indus-
try representatives when compared to their use in food, cos-
metics, and pesticides. Moreover, one of the reasons for
using nanomaterials in medicine is to use smaller and highly
targeted doses, therefore reducing systemic toxicity. To en-
sure safe and sustainable propagation of new and emerging
technologies, such as nanotechnologies, all possible impacts
from the applications of the new technology should be identi-
fied and described with respect to a particular application
sector. For example, comprehensive identification and de-
scription of benefits, risks, and uncertainties related to
‡ For example, Medicines & Healthcare products Regulatory Agency (MHRA) in
the UK. See website for details: https://www.gov.uk/government/groups/mhra-
innovation-office.
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nanotechnology and food, and nanotechnology and pharma-
ceutical products should be evaluated, rather than implica-
tions of nanotechnology as a whole. Descriptions of these im-
pacts may be theoretical or hypothesis-based, but they need
to be explored so that concerns are assessed, and to enable
policymakers to agree on, and develop, future research
priorities.
To date, there have been no studies gathering expert view-
points across nanomedicine R&D regarding the environment
risks from nanomedicine. However, one study from Portugal,
intended to understand how nanomedicine researchers per-
ceived ethical issues in nanomedicine, reported that of those
researchers (17 out of 22) who expressed potential risks from
nanomedicine, 6 (of the 17) mentioned environmental risks
of nanomedicine,33 although no further elaborations on envi-
ronment risks were done by the authors of this study. There-
fore in this paper, we discuss responses of experts (from re-
search, industry, regulatory/policy perspectives) on the two
key research questions: (1) the potential environmental haz-
ards and risks from nanomedicines, and (2) the adequacy of
existing risk assessment framework for assessing environ-
mental risks from nanomedicines.
Before describing the study methodology we define the
terms used in the paper. Althaus34 describes the concept of
risk used in various disciplines (e.g., sociology, history, and
medicine). For example, logic and mathematics see risk as a
calculable phenomenon, applied science and medicine see
risk as an objective reality, whereas sociology views risk as a
socially constructed phenomenon, and psychology as a be-
havioural and cognitive experience. This study elicits expert
responses on the type of risk assessment which is used
within the applied science and medicine fields as discussed
by Althaus,34 with special emphasis on environmental risk as-
sessment (ERA). Environmental and human health risk
expressed simply is hazard multiplied by exposure, where
hazard and exposure are assessed under laboratory condi-
tions using standard protocols and methods, and quantifica-
tion is done using certain assumptions and postulates.
Therefore, risk is the likelihood or probability of occurrence
of an event which is not desired. ERA conducted primarily
for chemicals (e.g. pesticides) helps decision-makers to set
environmental quality standards (EQS).
For medicinal products for human use, the European
Medicines Agency (EMA) needs an ERA as part of the market-
ing authorisation application submitted to the agency for any
new medicine, generic, hybrid product, fixed combination or
similar biological product. An ERA is also required if a
change is made in terms of the marketing authorisation, for
example, addition of a new disease indication, or increase in
dosage (known as type II variation). Justification for not sub-
mitting a complete ERA is acceptable if it is shown that there
is no increase in environmental exposure. The ERA has two
distinct phases: phase I: the screening phase, in which the
surface water concentrations of the active pharmaceutical in-
gredient (API) is calculated and a persistence, bio-
accumulation, toxicity (PBT) assessment is done if the
octanol–water partition coefficient is greater than 4.5, and
phase II: biodegradation, transformation and toxicity tests
based on OECD guidelines (e.g., OECD 301, 308, 201) on test
organisms specific to the environment compartment. The de-
tails of the tiered approach for ERA of medicinal products for
human use and lack of environment risk assessment frame-
work for medical devices in the EU have been discussed else-
where.27,35 However, two important points of note are that:
(1) the octanol–water partition coefficient is not suitable for
assessing behaviour of nanomaterials as it is based on equi-
librium partitioning36 (rather than kinetics) as a result of
nanomaterials accumulating at the interface rather than ef-
fectively separating,37 and (2) the OECD test guidelines are
currently undergoing extensive revision for nanomaterials38
to account for non-equilibrium behaviour, active receptor me-
diated uptake driven by surface interactions with biomole-
cules, agglomeration of nanomaterials in the standardised
(non-environmentally representative) test media and many
other limitations. Using the current test protocols could lead
to significant errors in both fate and hazard predictions and
thus overall risk assessment.
Risk assessment helps regulatory agencies to take deci-
sions based on evidence and “objective” analysis.§ In the case
of pharmaceuticals and medical devices, regulatory agencies
need to take into account the benefit–risk ratio of the prod-
uct. Also, potential environmental harm is not sufficient at
present to stop or prevent approval of a drug39 in the EU. In
cases where environmental harm is foreseen, proper informa-
tion and communication of risk management steps is ad-
vised by the USFDA.40,41 Our study aims to add clarity to the
exploratory discussions on environmental risks from nano-
medicine by presenting expert perspectives on this issue,
which has not been attempted previously. We conclude by
confirming, using Stirling's42 arguments, that in the case of
uncertainty and ignorance, risk assessment is not fool-proof
and may indeed be irrational since it does not fulfil the man-
date of evidence-based policy, leading to the conclusion that
a different approach to the governance of nanomedicine is
required.
Methodology
For this exploratory research study, in-depth interviews with
66 experts were conducted using a semi-structured question-
naire (customised for the expert stakeholder type, i.e., aca-
demic, industry, regulatory/policy or funder) shared in ad-
vance. The questions were informed by the theoretical
debates in the field of nanomedicine R&D, safety and regula-
tory studies, nanotoxicology and nanotechnology risk assess-
ment. Therefore, questions about the challenges in
§ A recent study by the EMA showed that even medicinal assessors are
influenced by demography and their own attitudes. For details see: http://www.
ema.europa.eu/docs/en_GB/document_library/Report/2012/02/WC500123226.pdf.
Moreover, risks are generally socially constructed. Though risk assessment is
said to be objective and a scientific process and hence is claimed to be positiv-
ist, risk assessment or any scientific process is value laden and subjective.
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nanomedicine R&D, intellectual property matters, gaps in
knowledge, challenges in the nanotoxicology domain, and
upstream public engagement were discussed, although the
results of analysing these questions are outside the scope of
this paper (they are partly reported in Mahapatra et al.43).
Only the qualitative analyses of questions related to potential
environmental risks from nanomedicine and adequacy of the
current risk framework for assessing environmental risks
from nanomedicines are presented here. Since risk is
constructed in specific sociotechnical contexts, both environ-
mental hazards and exposures were explored. The open-ended
questions asked are presented in the ESI.† Consent to be inter-
viewed was gained via email and permission from the expert
was sought before recording the conversation. The experts
were assured of the confidentiality and anonymity of their re-
sponses and were given the option of reviewing interview tran-
scripts. Table 1 lists the profiles of the experts interviewed,
categorised under broader stakeholder groups and research fo-
cus, while Fig. 1 maps the stakeholders along the medicine
and medical device research and commercialisation pathway.
To initiate the academic interviews, the scientists
contacted were principal investigators (PIs) of the EPSRC¶
nanotechnology grand challenge health care call.‖ Other than
EPSRC-funded PIs, other scientists researching in nano-
medicine were identified from published literature (last au-
thors, corresponding authors or well-established and leading
scientists in their domains; suggestions regarding nano-
medicine scientists from the initial interviewees helped con-
firm these selections), from information available online on
various conferences, and from lists of speakers or of mem-
bers of the advisory boards for such conferences. Scientists
researching on human and eco-toxicological aspects of nano-
materials, and social scientists researching on science, tech-
nology and society studies who were considered relevant to
the study, were identified from the literature and were
contacted to check whether they would be willing to take part.
The identified regulatory agencies were the agencies involved
in the pharmaceutical and medical device approval and agen-
cies involved in the protection of human health and the envi-
ronment. The industry representatives were identified from
the list of industries funded by Innovate UK (formerly the
Technology Strategy Board, UK) under the call for proposals
titled ‘Nanoscale technology enabled healthcare: building the
supply chain competition for collaborative R&D funding’.
Some industries were identified from the meetings organised
by the UK Nanotechnology Knowledge Transfer Network.
The interviewees were anonymised by grouping them into
categories. An alphanumeric code was assigned on the basis
of their area of expertise and the sequence of conducting the
interviews. For example, NMS 1 meant a scientist doing re-
search in nanomedicine and the first to be interviewed in
that group, and NMS 13 meant another nanomedicine scien-
tist and the thirteenth in that group to be interviewed. The
abbreviations used for the different areas of expertise/stake-
holders are: NMS, nanomedicine scientist; NMEn, nano-
medicine entrepreneur; HTOC, human toxicologist; ETOC,
ecotoxicologist; RC, research council; SS, social scientists; PP,
policy makers. Representatives from regulatory bodies and in-
dustry were named ‘Regulators’ and ‘Industry’ respectively.
Table S1 of ESI† provides the details of interviewees and
dates of interviews.
50 of the 66 interviews were conducted by the first author
alone. The remaining 12 were conducted by the first author
with both JRL and JRAC or with either JRL or JRAC. The inter-
views were transcribed verbatim and a general inductive ap-
proach44 was adopted to analyse the data in order to form a
link between the research objective and the qualitative data.
Repeated readings of the transcripts, systematic and rigorous
coding, and then combination of these codes into thematic
categories were performed to arrive at the findings discussed
here. These findings have been explained by frequent refer-
ence to studies in the field of nanotechnology and chemicals
where experts' opinions have been surveyed. For example, the
findings are related to outcomes from quantitative studies on
expert judgements on risks from chemicals,45–49 expert per-
ception on nanomaterial regulations, risks, and benefits,50–55
and surveys related to perceptions of risks related to nano-
materials and nanotechnology by industry and other
stakeholders.56–58
Given our objectives, a purely qualitative research design
was deemed most appropriate for our study, and the findings
presented here reflects this approach. Generally, qualitative
inquiries are an entry when a field is emerging and little re-
search has been done and there are very few hypothesis to
enable influence research policies.59 In qualitative research,
individual attitudes and opinions are crucial. Moreover,
Table 1 Profile and number of experts interviewed from each of the var-
ious stakeholder groups
Stakeholder group Number
Academics researching on nanomedicine 20
Academics researching on human health implications of
nanomaterials
4
Academics researching on environmental implications of
nanomaterials
5
Academics researching on research and innovation policy,
science-technology-society (STS) studies and regulatory
studies
9
Representatives from EMA, MHRA, Department for
Environment Food & Rural Affairs (DEFRA), Environment
Agency (EA), Health and Safety Executive (HSE), Health
Protection Agency (HPA) and notifying bodies
12
Representative of UK Research Councils (MRC, BBSRC,
NERC, EPSRC, ESRC)
8
Representatives of pharmaceutical and medical device
companies
8
Total 66
¶ Engineering and Physical Sciences Research Council (EPSRC) is the UK's main
agency for funding research in engineering and the physical sciences.
‖ The Research Councils UK had identified (2007–2008) nanoscience and nano-
technology as one of the priority themes of research and within which they
funded three areas related to the challenges facing society in the 21st century:
nanotechnology for healthcare; nanotechnology for the environment and nano-
technology for energy.
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research attempts to provide a more nuanced account of ev-
eryday human practices and understandings that goes be-
yond the limitations imposed by binary ‘yes’/‘no’ categories.
Hence the research questions evolved during the interview
process to accommodate different expertise areas and to ex-
tract the maximum value from each interview. Discussions
on environmental hazards and risks from nanomedicines are
still evolving, and at this stage it was considered important to
capture the diverse range of expert viewpoints, which we
hope can inform future large-n quantitative survey work. In
fact, we believe that the methodology and research design
used could be adopted to explore expert opinions in other
emerging technologies (such as synthetic biology). The em-
pirical qualitative data was analysed keeping in mind these
aspects and the results of the analysis is presented in the
next section. The quotes used here are verbatim (with only
very minor edits for clarity and brevity), but explanations and
their contextualisation are our own.
Results
Findings are presented in broad thematic categories that
emerged from the interview transcripts through coding (keep-
ing in mind the research questions). These thematic catego-
ries were to understand experts' opinions on possible hazards
and risks from nanomedicine and medical devices to the or-
ganisms in the environment and the adequacy of the existing
environment risk assessment framework and protocols. From
the analysis of the interview transcripts, two major groups of
responses emerged, which are analysed here: 1) interviewees
pointed out that the benefit–risk that is an inherent part of
research in medicines, i.e., the benefit of preserving human
health versus environmental or even human health risks,
needs to be considered; and 2) interviewees compared insig-
nificant risks posed by nanomedicines in the environment
(due to very small amounts) to more pervasive chemical pol-
lutants and global issues, such as climate change. The results
from the analysis are structured under four broad headings:
importance of assessing risk–benefit profile, views on envi-
ronmental hazards and risks from nanomedicines, views on
environmental hazards and risks from nano-enabled medical
devices (as the regulatory pathway is distinct for medical de-
vices), and views on the adequacy of existing regulations to
protect the environment from possible harms from medi-
cines. All interviews were conducted with experts in the EU
and hence the interpretation of their responses has been
contextualised in the frame of existing EU regulations for
medicines and medical device commercialisation and envi-
ronmental risk assessment of medicines for human use.
Fig. 2 provides a summary of the main responses of the ex-
perts interviewed in this study.
Importance of assessing risk–benefit profile
Some scientist interviewees researching nanomedicine and
representatives of medicine regulatory agencies emphasised
Fig. 1 General stages of (nano) medicine and medical device research, development and commercialisation onto which key stakeholders involved
in these stages are mapped. ERA: environment risk assessment. An ERA (without toxicity tests if threshold concentration in surface water is
estimated to be less than 0.01 μg L−1) is required to be submitted to the regulatory agency responsible for approving drugs along with the
application for marketing authorisation for new drugs. No such requirement exists for medical devices, though disposal of some medical devices
could be covered under the waste electrical and electronic equipment (WEEE) directive. The figure shows that toxicologists researching on effects
of pollutants on human health and the environment are ‘downstream’ of industrial research and innovation stages. Stakeholders not interviewed
are shown in italics and bold font.
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that benefits versus risk of medicines should be assessed.
Thus, before starting to answer a question on environmental
risks, a regulator dealing with approval of medicines explic-
itly mentioned the importance of looking at both risks and
benefits and explained that they have the mandate to assess
the benefits to public health from new medicines: “I just have
a question and it's always the same question. Why do you look
at the hazards and risks? Why don't you make a note in your
dissertation also about the potential benefits.....for us, it is very
difficult to look into this aspect of risks and hazards without
looking also at aspects like the expected benefits.” [Regulator 2]
They continued “I mean biodegradable, liposomal particles
or block polymer micelles....if you look at the benefits for example
you are reducing 100s of fold the level of doxorubicin, paclitaxel
and other chemotherapeutic agents.......this is, to me, already a
big advantage. On top [of that] you have the patients with less
mucositis, less carditis, so you need less of other medications.”
They also said that nanomedicines might result in re-
duced environmental concentrations of medicines because of
higher efficacy and targeting capacity in comparison to con-
ventional drugs.
“Nanoparticles are not the only pollutants, so maybe in the
future you can have minute portions releasing into the environ-
ment instead of big quantities of aluminum, big quantities of
other materials which are equally polluting. So I think it is im-
portant to keep the perspective. Nanostructures might at the
end of the day reduce pollution from medicines in many ways,
in addition to potential benefit to public health.” [Regulator 2]
Viewpoints of expert interviewees on environmental hazards
and risks from nano-therapeutics
a) Hazards possible, but risks unlikely. Experts inter-
viewees generally believed that nanomedicines can cause
Fig. 2 Summary of the main viewpoints (often contrasting) expressed by experts with regards to the two research questions: potential risks from
nanomedicines in the environment and adequacy of the existing ERA guideline. The central vertical portion (mass (used) and comparison with
other environmental issues) indicates that experts believed that environmental risks from nanomedicine are less worrisome and are lower down
the priority list of ‘everyday’ concerns. The three hexagons on the left hand side indicate the lack of knowledge and data about fate,
transformation and exposure of nanomedicines in the human body and environment and the need for revision of the environmental fate and
ecotoxicity test protocols. The proposed solution (dark green arrow) is to work across disciplines and create partnership amongst funding
agencies. The three hexagons on the right hand side indicate that hazards are possible from different forms of nanomedicines but environmental
risks are low, and certainly less than the benefits, thus supporting the idea of risk tolerance. The existing risk management approaches followed by
industries and required by regulators are robust, however, if the need arises, they can be adapted to manage the risks (e.g. via better disposal
guidelines, designing safer medicines, tweaking the risk management protocols/steps). This diagram is a snapshot of representative perspectives
commonly expressed by experts. ADME: absorption, distribution, metabolism and excretion.
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environmental hazards, though they were generally of the
opinion that these would not cause risks (as environmental
concentrations, and therefore exposure, would be low). The
prevalent idea of experts was that pharmaceutical manufac-
turers follow good manufacturing practices (GMP) and nano-
medicines will be very expensive, so wastage will be reduced.
Moreover, experts mentioned that hazards and risks (if any
due to use of medicines) will be local, i.e., in hospital waste
water, though the bioactive nature of medicines was
explained as the source of the hazard, i.e., medicines are
designed to either kill cancer cells or to influence specific
biochemical pathways, and hence they can influence similar
biological pathways in non-target organisms. The experts
gave the popular examples of oestrogens and anti-cancer
drugs to substantiate their viewpoints. One respondent, for
example, when asked whether nanomedical products might
pose ecotoxicological hazards and risks, said:
“I would say yes [to both hazards and risks]. For instance,
concerns over oestrogen – whether it comes from birth control
pills, or whether it comes from the farming industries that get
into waste streams – has affected apparently some fish
populations. And is there any reason to expect that just because
it's a nanomaterial and inorganic that somehow it might not be-
have as a drug? Things that interact with biological systems as
drugs [do] can obviously interact with biological systems of
other animals, there's no reason [to believe] that it might not
also affect things at a mechanical level in the environment.” [In-
dustry 04]
Several experts expressed the view that risks to the envi-
ronment would be negligible due to low volumes and dilu-
tion, and a few were confident that nanomedicines would not
cause any risks in near future. However, many experts gave
more cautious (and reflective) responses. Thus an expert
researching on health risks identified the problem with pol-
lution from pharmaceutical industry:
“So for the industries that are making the drugs, it's how ef-
ficiently I suppose these materials are actually going to be used,
what sort of waste there is, because where industry is concerned
it's likely that waste is going be dumped and so, I think disposal
of waste in the manufacturing industries that are making the
drugs would be the primary environmental hazard.” [HTOC3]
This interviewee went on to add that from medicines used
in hospitals or in clinics, the hazards would be negligible;
however, if use of the therapeutic is widespread and frequent
then there could be likely exposures and risk.
“With regard to actual clinical use, I think it's going to be a
lot lower as far as environmental hazard is concerned. If it's a
material that's excreted from the body then you have got hazard
as far as the water ways are concerned but again, it goes back
to the level of usage. If it's a very minimal use then I think that
the impact is not going to be that heavy. If it's something that
would be used, for example, to treat everyday cold and which
everybody would be taking on a regular basis and it is excreted
from the body then you've got a much more substantial prob-
lem. So it's similar I suppose to women taking contraceptive
pills and there have been concerns about the hormones that are
going into the waterways and how that affects feminization of
fish but you've got millions of women taking it on a daily basis
and so that's where you have the problem.”
This interviewee emphasised the potential of hazards and
risks from discharge from pharmaceutical manufacturing
plants as follows:
“I think unless nanomedicines are actually used to that ex-
tent, then I think that that's not going to be quite as much of a
problem. In the near future, it's very least but the manufactur-
ing side of things, I think is more problematic.” [HTOC3]
A typical response common to all expert groups (i.e., scien-
tists, industry representatives, and toxicologists) on the ques-
tion of potential environmental hazards and risks of nano-
medicines followed the line that nanomedicines can cause
hazards, but the amounts are negligible and they can be bio-
degraded or transformed in the body and the environment,
and then compared it with other industries or natural
nanoparticles. For example an industry representative
commented:
“It's very difficult to say that some of them won't get into the
environment. Whether they get in in the same form that they
went into the body is another matter. The body can do an awful
lot of metabolism. So there could be changes there. The whole
environment issue is a bit strange because there are nano-
particles out there, all around us, and nano seems to scare some
people.” [Industry 08]
This interviewee went on to say that the quantities are
likely to be insignificant and that medical products go
through rigorous toxicity testing for humans, however,
adding later in the interview that the toxicity is not tested on
environmental organisms like blue-green algae. They con-
cluded that:
“I think its [hazards and risks are] very unlikely and the en-
vironment is a huge place, there is a massive dilutional effect....
you can't say no [to hazard and risk], but I think it would be
very unlikely.” [Industry 08]
A social scientist emphasised the phrasing of the question
and said risk potential would be there, even if minimal, so
the possibility of no risk is unobtainable:
“Yes of course, it has the potential. This question says do
you think nanomedical applications might have the potential to
pose environmental health risks. But it would be very, very odd
to say no to that question, wouldn't it?” [SS02]
This expert asked what other interviewees' answers had
been and when told that majority had said that as the quanti-
ties are likely to be minute, risk is unlikely the interviewee
remarked: “So, it would be reduced risk but still some risk.”
b) Possibility of risks greater from nanomaterials used in
other industries. An oft-mentioned response for environmental
risks from nanomedicines was comparison to risks from
other sectors. The experts interviewed expressed more con-
cern for nanomaterials used in cosmetics, textiles and other
application areas. Several experts compared the risks from
nanomedicine with other industries, or compared it with
global environmental challenges, such as climate change and
air pollution:
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“Nanomedicines I think is probably an absolutely tiny com-
ponent compared to what else has been chucked out from other
industries.” [NMS 16]
However, despite the suggestion of negligible concentra-
tions of nanomedicines in the environment, some industry
representatives and academics researching nanomedicine
expressed concern about the health and consequently envi-
ronmental risks of engineered nanomaterials, which can be
aerosolised or are in powder form. The concern of hazards
and risks from powder or aerosolised nanomedicine forms
may be due to the many publications on health risks from
CNTs (e.g. reviewed by Donaldson et al. and Aschberger
et al.60,61) and historic and epidemiological studies on inhala-
tion of fine particulates and worker exposure to air contami-
nants in the workplace. Other studies, for example,31,51 have
reported that experts and industry representatives generally
view inhalation exposure or dry powders of nanomaterials to
be highly hazardous. Another probable reason for consider-
ing potentially higher hazard (and risk) from aerosolised
forms of ENMs could be that risk science has matured in the
case of human health impacts of airborne pollutants and ac-
ceptability of the risk assessment methodology has also been
achieved for such exposures and hence experts from acade-
mia and industry managers drew upon their knowledge to ex-
plain the possible risks of nanomedicine if in powder form,
or if nanomedicines are administered through the nasal
route. However, a key question here is whether this is “folk
theory?**”62 Experts emphasised that the nanomedicines
they were working on are generally in liquid or are nano-
particles only when in aqueous media. For example, an aca-
demic expert involved in developing nanomedical applica-
tions who has also established a company said:
“First of all the nanoparticles that we make, they are nano-
particles only once they are in contact with aqueous media....
The nanoparticles that we should be concerned about are
those that can be aerosolised, those that can be in the atmo-
sphere. You can breathe them in. Most of the NPs under devel-
opment are not those types so they are not being made as
dusts and fine powders. They usually are made as an aqueous
dispersion....and they will only cross the biological barriers
once they are introduced into the body and they are normally
introduced by ingestion or by injection; those are the two main
routes.” [NMEn07]
Moreover, no novel environmental risks from nano-
medicine were suggested by most experts and hence no spe-
cific nanomedicine related change in regulations was re-
quired, a finding similar to Silva Costa's34 study where
nanomedical researchers did not think that ethical issues
specific to nanomedicine need to be considered.
Views of expert interviewees on environmental hazards and
risks from medical devices
Most experts mentioned that medical devices made with
nanotechnology would not be hazardous to the environment
as the nanomaterials would be embedded within a non-
nanomaterial and consequently there would not be any direct
exposure. Hansen et al. (2008)63 developed a categorisation
framework for nanomaterials which classified consumer
products where nanomaterials are suspended in solids as
having no exposure. This conviction that embedded or bound
nanomaterials would not cause harm or raise less concerns
has been reported by Weil in her survey of 22 firms in the US
Midwest64 and by Capon et al.32 in their survey of Australian
scientists, representatives from industry and government,
and lay persons. However, some experts mentioned that gen-
eral wear and tear can cause some exposure. The possibility
of human health risks from wear debris of medical implants
such as replacement hip-joints have been reported and novel
mechanisms of effects elucidated (for example, DNA damage
caused by influencing the cellular signalling pathway without
compromising the structural integrity of cells or the cell
barrier).65,66
Interestingly, some experts developing nanomedicines and
representatives from regulatory bodies mentioned designing
medical drugs and devices in such a manner that they have
minimal negative environmental implications, the so-called
safer-by-design or benign-by-design considerations.67 For ex-
ample, one expert from a regulatory agency said regarding de-
sign of devices:
“Scientists are, for example, coating those nonbiodegradable
devices in a way that once they go into the environment they be-
come susceptible to light. So the beauty of the nanoparticles,
even the activatible implantable ones, is that you can play with
the physical properties, the optical properties whereby as soon
as they go out of the body they can be self-destroyed....if it was
[that] the cumulative amount in the environment would pose a
hazard, you can find a way to make them vulnerable to the envi-
ronment, so difference in temperatures, for example, can break
the particle or light exposure can break the particle.” [Regulator
02]
On the other hand, high attrition rates of drug candidates
(e.g. approximately 40% of drugs fail in the preclinical phase
due to non-clinical toxicity68) and the need to make drugs
with desired pharmacokinetics and efficacy pushes consider-
ations regarding environmental biodegradability lower down
in the priority list. For example, in a study by Doerr-MacEwen
and Haight,69 where experts from academia, industry, and
government from North America and Europe were consulted
to gain their perceptions on environmental risk management
from pharmaceuticals, it was reported that incentives for
green drug manufacturing strategies were ranked low both in
terms of effectiveness and feasibility (7th and 8th rank re-
spectively out of 8 environmental risk management strategies
suggested in the study) for risk management. Moreover, in-
dustry representatives in that study mentioned that the
** A point to note is that very few conventional medicines (e.g. medicines for
asthma, migraine) are administered through nasal or inhalation routes and
hence the question arises whether this could be a “folk theory”, as per Arie Rip,
i.e. a “pattern that evolves in ongoing practices, and serves the purposes of the
members of the various practices”; however, these claims are not systematically
checked.
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function of a pharmaceutical was wholly dependent on its
structure and informed about the high attrition rates of
drugs in the drug research and development process, and fur-
ther pointed out that commercialisation of medicines would
become more complicated if drugs need to be biodegradable
in the environment.69
Using biodegradable substrates (though substances after
biodegradation can give rise to toxic products) and not using
plastic casings for lab-on-chip devices was another design
feature mentioned by interviewees. A social scientist men-
tioned that rather than having end-of-pipe solutions and
more regulations, it is better to have a technological fix to
make a product less risky to the environment. The case of
small amounts of nanomaterials present in medical devices
was also discussed by the interviewees. They also noted that
contaminated medical devices are incinerated at their end-of-
life and hence are not likely to pose hazards and risks (nano-
materials are distributed majorly between bottom ash and fly
ash when products containing nanomaterials are incinerated,
though the distribution depends on the nanomaterial type
and size, combustion conditions and design of the incinera-
tors70,71). However, whether the experts meant hazards and
risks to human health or the environment was not explored
further, because mostly these responses were preceded by
discussions regarding safety to human health. Many experts
mentioned the need to have proper disposal instructions, but
had confidence in the current disposal guidelines of medical
waste and their implementation success. However, the poor
state of reporting of medical waste in the UK and US have
been mentioned elsewhere.25
Views of experts on adequacy and adaptation of the current
environment risk assessment framework for nanomedicines
Experts researching the topics of human toxicity and
ecotoxicity, i.e., downstream experts, and a few experts
researching nanomedicines (upstream experts) commented
that in principle the current risk assessment procedure is ap-
plicable to nanomedicines and that only some adaptation is
required for test systems, standards, and protocols for hazard
identification, characterisation and exposure assessment. A
need for modification of current test media and protocols
has been shown in some studies, see for example, Park
et al.72 and Casey et al.,73 and establishment of suitable dose
metrics has been discussed for conducting various exposure
assessment studies.74–77 However, the majority of experts
interviewed, including some experts researching the toxic ef-
fects of pollutants on human health and the environment,
were unaware of the ERA guidelines for pharmaceuticals for
human use or the need for ERA as a step (if needed) in the
drug approval process.
Responses to the question on adequacy of the current ERA
for medicinal products for human use (the guidance docu-
ment was shared with experts with the questionnaire) elicited
contradictory viewpoints. An eco-toxicologist aired their dis-
agreement with the current broader scientific consensus
about the inadequacy of current regulatory toxicity endpoints
to reflect chronic effects of nanomaterials. The expert
emphasised that new toxicity endpoints specific to nano-
materials are not needed and that current endpoints meant
for bulk chemicals are sufficient:
“I think the endpoints are fine....I think probably the tests
are fine as long as they're performed in the right way....I really
don't think we need new endpoints for nanomaterials. We just
need to think about refining the test so that we are able to do
them with nanomaterials and that the results are meaningful in
the natural environment.” [ETOC2]
This expert continued:
“I know a lot of academics say that we need new ecotox for
nanomaterials, but I think the endpoints have been established
for years and they are there to protect different taxonomic
groups. There's no reason why we should say a biochemical end-
point or histological endpoint for a nanomaterial and not do it
for other chemicals. So, I really struggle with some of the aca-
demics that are really trying to push subtle [toxicity] endpoints.”
[ETOC2]
The excerpts above indicate one extreme end of the spec-
trum of opinions regarding adequacy of existing risk assess-
ment frameworks for nanomaterials. At the other end an-
other extreme viewpoint from an eco-toxicologist was that
risk assessment of nanomaterials should be viewed through
a completely new lens if novelty of nanomaterials is the key
issue.
“....I have formulated another hypothesis saying that it is not
possible to adapt. I think we need to start on a clean sheet of
paper and that's because as far as I read most of the guidelines,
now it is [for] ecotoxicity, our underlying assumption is mainly
that we are dealing with dissolved chemicals....” [ETOC1]
These contrasting views and the divergence regarding test-
ing methodologies, standards, and protocols are not new in
the “young science of risk assessment”.45 A survey of UK toxi-
cologists showed that these scientists disagreed on the ex-
trapolation of animal models to sufficiently predict risks to
human health.47 In the case of nanomaterial risk assessment,
consensus expert opinion is that the risk assessment frame-
work for bulk conventional chemicals can be used for nano-
materials; however, it has been discussed that the properties
of nanomaterials (especially for nanomaterials less than 10
nm) are different than those of bulk materials and hence the
procedures for conducting risk assessment will need
customisation.78–80
Some nanomedicine experts and industry representatives
mentioned that as a rule of thumb they treat the nano-
materials that they work with as hazardous, since they do not
have complete understanding or knowledge of their toxicity,
and hence follow the necessary rules of managing and han-
dling hazardous waste. The representatives from industry
and some of the nanomedicine scientists in academic institu-
tions indicated that they are using whatever knowledge they
have to deal with risks, and proactively engage with the
Health and Safety Executive (HSE) to sort out issues.†† Simi-
larly, some [NMS 09 and NMS 19] emphasised the difficulty
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of filling the existing COSHH‡‡ forms (designed for tradi-
tional chemicals) and the need to adapt the forms for nano-
materials. This indicates a certain amount of concern and
care on the part of the researchers, a kind of moral responsi-
bility as presented by Ladd81 which is necessary in the con-
text of the knowledge gaps, uncertainties and lack of regula-
tion or specific prescriptions for behaviour which is pervasive
in the nanotechnology field, indicating a strong alliance with,
for example, the EC's code of conduct for responsible nano-
science and nanotechnology.82
Only one expert (an eco-toxicologist) mentioned the
threshold or trigger value of predicted environmental concen-
tration (PEC) to do an environmental risk assessment as not
being correct for nanomedicines, because of the value being
a mass-based metric and hence not taking into account the
unique functionality of the nanomedicines, and indeed the
ongoing debate in the broader nanomaterials safety commu-
nity of the appropriate dose metrics being either surface area
or particle number.74
When asked about the applicability of the partition coeffi-
cient (logKow values) to assess the persistence and bio-
accumulation potential of nanomaterials, most of the experts
(except eco-toxicologists) initially interviewed acknowledged
their lack of knowledge regarding the question and asked for
further explanation. It was interesting to note that human
toxicologists interviewed did not know about the use of log
Kow, indicating strong disciplinary orientations. So, it was de-
cided that this will be asked only to those experts who would
be able to answer. The experts who were posed the question
on applicability of logKow for ERA of nanomaterials unani-
mously responded that logKow was not a good surrogate and
they stated that it was not even fully applicable to conven-
tional pharmaceuticals for assessing persistence. For nano-
medicines, they suggested that finding logKow value is com-
plicated and they responded by saying it will need to be
assessed on a case-by-case basis. Experts (all eco-toxicologists
and representatives of a regulatory agency) who had an un-
derstanding of the concept expressed uncertainty about esti-
mating it in the laboratory. Three eco-toxicologists [ETOC1,
ETOC2, ETOC3] stressed that octanol–water partition coeffi-
cient was not the right proxy for bioaccumulation and one
further added that the distribution coefficient is not even the
right predictor of bioconcentration: “I don't think we should
be thinking about the log Kow for nano materials or Dow.”
[ETOC2]. The challenges of, and issues with, measuring
octanol–water partition coefficient for nanomaterials have
been discussed elsewhere.27,35
Interestingly, some experts researching on nanomedicine
said that they need to consult with their colleagues who
might be able to tell them how to go about measuring log
Kow. The medicines regulatory agency experts indicated that
the criterion of logKow for medicines is one area that is being
looked into. One of the ecotoxicity experts interviewed got
back later after discussing the issue with a material scientist:
“The log Kow measurement is a bit of a moot point in terms
of nanomaterials – specifically if they are dissolved they are no
longer nanomaterials and should be therefore treated as a nor-
mal chemical. Instead there should be a measurement of the af-
finity of the surface of the nanomaterial to a polar or non-polar
liquid....” [ETOC5]
Several experts from academia and the policy makers were
unaware of the regulatory requirements regarding ERA of
pharmaceuticals. Lack of awareness of regulations has been
reported by Marquis et al.,83 where they conducted a thought
experiment with bench scientists researching on nano-
medicines to understand the requirements to get approval
for a medical product from the USFDA.
Five scientists researching nanomedicines mentioned
safety to patients and health care staff responsible for admin-
istering nanomedicines to patients in their responses, and
described their own practice in the laboratory regarding fol-
lowing the necessary safety rules, indicating that risk framing
by scientists is based on their subject expertise or institu-
tional affiliations, as has also been observed elsewhere.49,84
This might be due to the difficulty in imagining that ques-
tions on environmental risks of nanomedicine could be
asked, although the aim of the research was detailed in the
introductory mail and the questionnaire and associated docu-
ments were sent in advance, or was perhaps because stress
and time limitations being part and parcel of academic life,85
meant that they had not had the time to go through the
questions.
The novel properties of nanomaterials and hence new
risks, the lack of knowledge of the fate and behaviour of
nanomaterials in the human body as well as the environ-
ment, and the associated uncertainties have been widely
discussed in the nanotechnology literature. Below is an ex-
cerpt from a detailed discussion:
“The first part of any risk assessment is probably the formu-
lation of exposure assessment. So, some of the assumptions in
exposure assessment don't fit the way the nanomaterial would
behave for they don't capture the fact that they're dynamic, that
they change in time.” [ETOC3]
This expert, and some others, believed that the current
risk assessment framework for chemicals was applicable for
nanomaterials; however, they detailed the uncertainties and
challenges involved in conducting an environmental risk as-
sessment of nanomaterials:
“The basic principles of risk assessment are fine. The devil
is in the detail. So, transformation is important....for example,
do you want to risk-assess materials even though they're modi-
fied in the environment or do you want to assess the modified
materials? You can do the hazard tests, but as in any form of
risk assessment, what those mean in terms of real affect is less
easy to interpret because of this dynamic nature change.”
[ETOC3]
A social scientist clearly indicated the need for communi-
cating uncertainties and knowledge gaps: “I think it's
†† An interesting point to note here is the absence of any mention of the Envi-
ronment Agency in the discussions.
‡‡ COSHH: control of substances hazardous to health.
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important not to just focus on the risks but also to take seri-
ously the prospect of uncertainties and areas of ignorance as
well.” [SS03]
Discussion
Use of nanomaterials in health care is perceived to be benefi-
cial by experts (as expressed by the experts interviewed in the
current research and in other studies) as well as the public.86
In contrast, environmental pollution risks from nano-
materials are generally of lower concern to experts than ani-
mal and human health risks54 due to expected minimal expo-
sure. They reasoned that nanomedicines would undergo
transformation in the body as well as in the environment,
which could make them less hazardous (although this is not
currently tested for nanomedicines, for nanomaterials used
in other applications, transformations in media have been
shown to increase87 or decrease toxicity88,89). The presence of
traditional PPs (e.g. oestrogens, antibiotics, painkillers) in
surface waters suggests this is too simplistic an argument as
evidenced by feminisation of fish and behavioural
changes.90–92 Pharmaceutical products are considered to be
micro-pollutants/emerging contaminants, and hence these
substances are not controlled by emission limits. Therefore,
in the UK, discharges of PPs from waste water treatment
plants are not under regulatory control and neither are PPs
being monitored from an enforcement perspective in surface
waters, although the increasing awareness of environmental
impacts of PPs has led to the addition of diclofenac and hor-
mones 17β-estradiol and 17α-ethinylestradiol to the watch
list of substances monitored in surface waters under Direc-
tive 2008/105/EC (as amended by Directive 2013/39/EU) of the
European Parliament “for the purpose of facilitating the de-
termination of appropriate measures to address the risk
posed by those substances”.93 It is likely that these pollutants
will come under the remit of the Industrial Emissions
Directive (2010/75/EU) and Environmental Quality Standards
Directive (2013/39/EU) in due course.
With regard to the prevalent perception on GMP followed
in pharmaceutical manufacturing sites, studies have reported
the presence of PPs downstream of pharmaceutical industries
in developed countries.94 For example, a recent study
reported that the monitored amount of PPs in effluents from
waste water treatment plants (WWTPs) receiving waste water
from pharmaceutical industries was 10 to 1000 times higher
than typical WWTP effluents (where generally the concentra-
tion of PPs is less than 1 μg L−1) which don't receive dis-
charge from pharmaceutical industry waste water.95 Hence
discharge from pharmaceutical industries can be an impor-
tant source of PPs into the environment,§§ contrary to the
viewpoint of the experts interviewed in this study. Interest-
ingly, literature published by pharmaceutical industries
themselves report estimated concentrations (lower μg to ng
L−1 range) in effluent from their manufacturing and formula-
tion units that are lower than what has been reported in the
academic literature. For example, by using a mass balance
approach, Roche (Basel, Switzerland) estimated the concen-
trations of active pharmaceutical ingredient (APIs) to be in
the range 0.01 to 38 μg L−1 in their effluent,96 and excipients
were estimated to be in the range ∼38 μL−1 to 22.5 ng L−1.97
While production data from plants manufacturing pharma-
ceuticals and data from pharmaceutical formulation units
are generally not available to the public and estimated and
monitored concentrations show wide divergences, neverthe-
less it is clear that the pollution aspect from pharmaceutical
manufacturers exists. Moreover, it is well established that
non-human stakeholders, i.e., the environment, are rarely
paid much attention in risk assessment.98 Furthermore, risk
and responsibility are defined and perceived in a particular
socio-cultural-economic situation and are highly contextual
to a particular sector.31,99 In some sectors like health, tolera-
bility and acceptability of risk100,101 could be different when
compared to other sectors such as food or transportation.
In a few instances, a lengthy discussion took place be-
tween the interviewee and the interviewerĲs) with regard to
risk aversion, especially in the UK context. It was explained
how the risk averse attitude is thwarting innovation and mak-
ing the life of academic scientists more challenging. These
same experts expressed unhappiness with the current health
and safety guidelines due to their sometimes ‘unnecessary’
cautiousness (precaution), and preferred not to be burdened
with more new rules and regulations regarding health and
safety of nanomaterials. Some experts explained the hazard-
ous substances handled in chemistry laboratories and in
comparison expressed the possible benign nature of nano-
materials that they were using. Most scientists developing
medicines, and industry representatives, explained the con-
cept of possible risks and hazards by citing their own re-
search work and the materials they use. For example, the
nanomaterials they were using were either abundant in na-
ture, e.g. silica, or were considered to be biodegradable, like
polymers (can be persistent if not biodegradable), proteins,
and lipids. Robichaud et al.102 used an insurance industry
risk quantification protocol and applied it to industries
manufacturing chemicals and compared them with nano-
material manufacturing and found that environmental risks
from manufacturing nanomaterials were less than or equal
to those from other chemicals such as manufacture of aspirin
and petroleum refining. However, novel properties of nano-
materials, their persistence, and potential unique modes of
action can cause environmental risks and remain to be stud-
ied. The nanoĲeco)toxicology field is very new and filled with
uncertainty.103
Additionally, detailed discussions took place on the com-
plexity of nanomaterial systems, the immense possibilities to
create a plethora of nanomaterials, their varied properties
which would make it challenging to put them in a particular
class or category, the current inability to detect them both in
§§ The monitored concentrations of PPs in the receiving waters of pharmaceuti-
cal manufacturing units in both developed and developing countries have been
reviewed by Larsson (2014). D. G. J. Larsson, Philos. Trans. R. Soc., B, 2014, 369.
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the body and the environment, their unpredictability in the
human body and environmental systems, their dynamic
nature, toxicity, biodegradability or biopersistence, bio-
accumulation and excretion being dependant on shape, size,
surface functionality, and surface chemistry, and associated
uncertainties and knowledge gaps.
Generally, it is accepted that scientists researching risks
from pollutants to human health and the environment, or ex-
perts involved in risk assessment, will have strong views
about risks,84 however, in this research it was found that
none of the experts were overly concerned about the hazards
and risks from nanomedical applications. They agreed there
was the possibility of hazards but expressed their reservation
about environmental risks from nanomedicine. However,
some of them expressed their satisfaction that research was
being done to explore environmental risks from nano-
medicine and that it was not a neglected area. For example,
SS 01 (well-known scientist involved in the deliberations on
science and innovation governance) was asked: are the cur-
rent [environmental] risk assessment test methodologies and
protocols fit-for-purpose for nanomedicine? Are you aware of
them? To which the response was that the person was not
aware of them and could not comment on their applicability,
not being an expert in environmental risk assessment,
adding “I would be worried if there weren't any such protocols.
I would be worried if there were no researchers researching into
it. It's important that those things are done.”
All experts were enthusiastic about applications of nano-
technology in human health. Some interviewees included dis-
claimers that benefits and risks need to be compared and
also that comparison should be made with other conven-
tional chemicals (e.g. endocrine disruptors) and other global
environmental problems like climate change.
Overall, the interviewed experts in this study were not very
concerned about environmental risks from nanomedicine
and prided themselves in leading the way with respect to
health and safety in their laboratories and workplaces. Some
experts gave examples of their proactiveness in engaging with
the HSE to discuss ways to handle the nanomaterials/nano-
medicines which they were manufacturing. They gave the im-
pression that they were very diligent with respect to health
and safety and designing safety into products. Industry repre-
sentatives talked about the risk management controls which
they already have in place. Generally industries have indicated
they know the best health, safety, and environment measures
that need to be taken in a given scenario.51,64 Ability to work
with radioactive materials was frequently cited as an achieve-
ment or a triumph against hazardous materials and hence
the confidence that risks can be managed or controlled (abil-
ity to control risk generally results in lower perception of
risks) with increasing knowledge and technical know-how.
All but one of the UK research councils shifted the respon-
sibility of assessing the environmental risks to the Natural
Environment Research Council (NERC), whose remit includes
funding research on environmental issues. Experts from this
research council in turn informed that the regulatory agen-
cies dealing with medicines would be most appropriate to be
approached on environmental risk from nanomedicines.
Even the regulatory agencies with the responsibility to deal
with environment issues suggested that the regulatory agency
dealing with medicines would be in the best position to an-
swer questions related to adequacy of regulatory frameworks
for ERA. This indicates that the pharmaceutical sector is a
very distinct sector with regard to downstream implications
with very few overlaps between various governance agencies
(both funding and oversight) and it seems responsibility can
be easily attributed (or passed to) someone else. However, an
interesting point is that research on pollution from tradi-
tional pharmaceuticals is funded by NERC and environmen-
tal pollution issues are addressed by the environment
agencies.
It was intriguing to note the admiration that scientists
had for the pharmaceutical industry sector and its regulatory
bodies, and the confidence they had in them to follow proper
health and safety protocols. Generally, experts have been
shown to have more confidence¶¶ in government agencies
dealing with risks,31 perhaps due to the knowledge that regu-
latory agencies have experts who are qualified in their subject
areas (i.e., PhDs) whereas the public appears to have less
trust in government regulatory agencies and pharmaceutical
industries.32,104 The experts interviewed here repeatedly men-
tioned the stringent regulations in the pharmaceutical sector,
the ‘smartness and intelligence’ of the pharmaceutical indus-
try, and the regulatory preparedness, which contrasts with
the poor reputation of pharmaceutical companies.105,106
However, regulators did not see themselves as being prepared
for handling the regulatory challenges that would be posed
by nanotechnology products and expressed the need for inter-
action across disciplines. This observation is very much
aligned with what other investigators have reported. Beaudrie
et al.52 in their survey of 254 US-based scientists, decision-
makers, and environmental health and safety (EHS) scientists
reported that regulatory scientists did not consider them-
selves fully prepared to manage risks from nanotechnology
applications whereas scientists and EHS experts perceived
regulators to be more prepared (than the regulators' self-as-
sessment) for managing risks from nanotechnologies. A simi-
lar uncertainty on the part of the regulators was reported in
their survey of experts from both the US and Canada,53 and
also by Helland et al.,58 who gathered perceptions of experts
from academic, health and safety agency and industry.
Another interesting outcome observed from the interviews
across the spectrum of expertise was that the questions from
one area could promote discussion or even follow-up ques-
tions to colleagues from different disciplines. For example, a
team of scientists developing a nanomedical application
started discussing the implications of logKow for their
¶¶ It is important here to note that in the risk perception literature trust and
confidence have been nuanced. Earle (2010) mentions ‘confidence’ as
calculative trust where trust is based on past behaviour or knowledge about a
process. T. C. Earle, Risk Anal., 2010, 30, 541–574.
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product, and a scientist researching environmental impacts
of nanomaterials was intrigued when they were shared exam-
ples of studies which found excretion of the nano-form in the
urine and/or faeces. This indicates that an interview process
can also prompt reflexivity thereby promoting modesty and
pluralism in viewpoints of experts.107
Conclusions
Discussions on nanomedicine to date have focused on regula-
tions,108,109 public perception of applications of nanotechnol-
ogy and nanomedicine,110,111 public engagement for defining
nanomedicine funding strategy,112 or on ethical issues of
nanomedicine.113 Very few studies have explored the environ-
mental risks from nanomedicine, especially none on expert's
perceptions on environmental risks from nanomedicine,
which is exactly what this study has done.
The instinctive and spontaneous discussion on possible
human health risks from nanomedicine shows that the con-
cept of environmental risk assessment seems to be distant
and distinct (except for specialist eco-toxicologists). However
it was heartening to know that health and safety issues have
become mainstream and habitual throughout a product value
chain, although potentially with some naiveté and over-
confidence from nanomedicine-developing academics. None-
theless, our research highlights a significant gap in terms of
awareness of environmental regulations as well as a lack of
orientation towards an ecosystem perspective. Thus, a signifi-
cant conclusion from this paper is a call for effective commu-
nication and deliberation strategies to reduce this gap, and
to raise awareness regarding the environmental aspects of
risk assessment of nanomedicines, and more broadly of
pharmaceuticals. More collaborative working across disci-
plines which includes social scientists can be made manda-
tory by funding agencies (e.g., the way EPSRC funded the
grand challenge for nanotechnology for health care), espe-
cially since social scientists are aware of the subjective nature
of risk and that risk can never be nullified. Furthermore,
EPSRC's strategy of funding a public engagement exercise be-
fore the grand challenge call, to identify and prioritise the
funding areas in nanomedicine, is also a useful strategy to
get stakeholders involved in research topics.112
Risk perception is not unidimensional in the sense that
risk is not an ‘objective’ fact described only by the probability
of harm; rather, risk is a multidimensional socially
constructed concept and is dependent on many factors,
thereby making risk assessment subjective in nature and
hence not value-free, even though guidance documents on
risk assessment state that risk assessment is a scientific pro-
cess. For example, the EMA did a study to assess what influ-
ences medicinal assessors‖‖ regarding decisions on approval
of medical products which found that variables such as gen-
der and number of years as an assessor can influence percep-
tion of risks and benefits. Science is assumed to be objective
in its positivist philosophy; however scientific ‘facts’ are
contested often enough, for example, dietary fat and choles-
terol and their link to coronary heart disease114 and the re-
cent controversy on the carcinogenic potential of gly-
phosphate.115 Also, social science scholars have shown the
influence of micro- and macro-social interests in shaping re-
search and its outcomes.116–118 Moreover, Stirling42 has ar-
gued as to why, in conditions of uncertainty, ambiguity, and
ignorance, risk assessment – a reductive technique – is nei-
ther science based nor rational. Therefore, anticipatory risk
governance needs to be conceptualised upstream of technol-
ogy or product development and commercialisation.
Special risk governance of active and complex nano-
systems was called for by Renn and Roco.119 Furthermore,
Renn120 proposed a “risk escalator”, where he suggests in-
volving various stakeholders to resolve risk issues induced by
complexity, ambiguity, and uncertainty. Similarly, the precau-
tionary principle can deal with risks in conditions of uncer-
tainty. However, the precautionary principle is rarely
discussed with respect to pharmaceutical development be-
cause risks from pharmaceuticals to humans are more
individualised and can be controlled, and are not as diffuse
as environmental risks for which the principle was devel-
oped.121 Some other related anticipatory risk governance ap-
proaches suggested are multicriteria decision analysis and
weight of evidence approach for nanomedicine research and
development.67,122 Linkov et al. recently made a strong case
on collaborative, adaptive, and integrative risk governance for
early assessment of emerging technologies.123 Furthermore,
such risk governance approaches is a step towards responsi-
ble innovation.124 Environmental impacts of nanomedicine
are likely to be negligible for some years. Moreover, robust
data and evidence are needed to change existing policies and
formalise regulatory criteria, which calls for further research
to address basic conceptual problems, such as: (1) what are
the trigger limits in the environment in terms of mass con-
centrations of nanomedicines; (2) how to establish bio-
accumulation criteria and appropriate test assays; and (3)
what to do in the case of complex nanomedicines. Specifi-
cally, we suggest that risk assessors consider inclusion of a
specific test for the durability of the complex between a nano-
carrier and the therapeutic agent in environmental media as
a means to determine probability of release, as once the ther-
apeutic agent is released from the carrier, the nano-specific
concerns regarding mobility, enhanced or receptor mediated
uptake etc. could disappear. Such an approach has also been
proposed as a means to regulate nano-pesticides, for exam-
ple.125 A point worth mentioning here is that the medicines
regulatory agencies of the US and the EU have not been lag-
ging much behind innovation in terms of deliberating on the
impacts of new and emerging technologies which shows that
they are trying to keep up with the science. For example, an
International Workshop on Nanomedicine was organised by
the EMA as early as September 2010 where the need to review
environmental guidelines was discussed,126 (all the
‖‖ http://www.ema.europa.eu/docs/en_GB/document_library/Report/2012/02/
WC500123226.pdf.
Environmental Science: Nano Paper
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 1
1 
Ju
ly
 2
01
8.
 D
ow
nl
oa
de
d 
on
 8
/2
0/
20
18
 5
:4
2:
26
 P
M
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n-
N
on
Co
m
m
er
ci
al
 3
.0
 U
np
or
te
d 
Li
ce
nc
e.
View Article Online
1886 | Environ. Sci.: Nano, 2018, 5, 1873–1889 This journal is © The Royal Society of Chemistry 2018
presentations of the workshop are on the EMA's website)
and the recent publication “Determining the Need for and
Content of Environmental Assessments for Gene Therapies,
Vectored Vaccines, and Related Recombinant Viral or Micro-
bial Products” from the USFDA41 discusses how the industry
can go about preparing environmental assessments for
these emerging therapeutics. The customisation of OECD
methods for sediment and aquatic testing specific to nano-
materials is under way, which when completed can be in-
corporated in the guidance document for environmental
risk assessment.
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